Quantcast

Industry news that matters to you.  Learn more

Archives for November 2013

CirQuest Labs Expands Predictive Laboratory Analytic Capabilities

CirQuest Labs recently announced it is expanding predictive laboratory analytic capabilities to meet the growing needs of clients seeking to determine how persons’ genetic differences may affect their response to drug therapy. The breakthrough analytical technology and companion bioinformatics makes it possible to determine the effects of genetic variation on drug efficiency, drug metabolism and drug toxicity early in the drug development process.

Extensive Scientific Data Supports the Clinical Validity of Pharmacogenomic Testing for Predicting Patient Response to Psychiatric Medications

AssureRx Health, a leading personalized medicine company, recently announced that the International Review of Psychiatry published an extensive review that validates the clinical use of pharmacogenomic testing to help predict patient response to psychiatric medications and improve treatment outcomes.

Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, recently announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor

Researchers from GeneAssess, Inc., a Foundation Venture Capital Group portfolio company, recently announced the publication of the genetic studies that led to the identification of the FRY gene as a breast cancer susceptibility suppressor gene.

New Biomarkers in Rheumatoid Arthritis

Hasselt University and INOVA Diagnostics recently announced the completion of an exclusive, worldwide license agreement and research collaboration for technology developed at the University. This technology represents an important advance in the diagnosis of Rheumatoid Arthritis (RA). VIB, the Flemish life sciences research institute, assisted Hasselt University in patenting the RA markers and in the license negotiations.